Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged securities fraud, claiming the company misrepresented its AI capabilities and financial health to investors [1][4][5]. Company Overview - Tempus AI, Inc. is publicly traded on NASDAQ under the ticker symbol TEM and has been accused of branding itself as an AI company despite limited revenue generation from AI solutions [4]. - The company primarily generates revenue through acquisitions, genomic testing, and data licensing agreements [4]. Allegations and Concerns - The lawsuit alleges that Tempus misled investors about the security and expansion of its data licensing agreements, particularly with AstraZeneca, and claimed high revenue potential from its acquisition of Ambry Genetics [4]. - A report by Spruce Point Capital Management raised concerns about Tempus' management practices, overstated AI capabilities, and aggressive accounting [5]. - Specific issues highlighted include the CEO's history of cashing out before public shareholders incur losses, connections to troubled companies, and recent revisions in financial guidance indicating weaknesses in core operations [5]. Financial Impact - Following the release of the Spruce Point Report, Tempus' stock price dropped by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [6]. Legal Information - Investors who purchased Tempus stock between August 6, 2024, and May 27, 2025, are eligible to participate in the class action lawsuit, with a deadline to request lead plaintiff status by August 12, 2025 [6]. Legal Representation - Shamis & Gentile, P.A. is representing the impacted investors and has a history of recovering over $1 billion for consumers affected by securities fraud [7].